2016
Chapter 57 Second-Line Hormonal for Castrate-Resistant Prostate Cancer
Parihar J, Kim I. Chapter 57 Second-Line Hormonal for Castrate-Resistant Prostate Cancer. 2016, 533-540. DOI: 10.1016/b978-0-12-800077-9.00057-8.Peer-Reviewed Original ResearchCastrate-resistant prostate cancerProstate cancerHormonal manipulationHormone-sensitive prostate cancerSecond-line hormonal manipulationsSecond-line hormonal therapySecond-line treatment optionAssociated response ratesInitial systemic therapySecondary hormonal manipulationsSecond-generation antiandrogensFirst-generation antiandrogensAntiandrogen withdrawalARN-509Hormonal therapyMainstay treatmentAbiraterone acetateAndrogen suppressionSystemic therapyAndrogen deprivationSuch patientsTreatment optionsTherapeutic responseDisease progressionResponse rate
2014
Concern for overtreatment using the AUA/ASTRO guideline on adjuvant radiotherapy after radical prostatectomy
Kang J, Ha Y, Kim S, Yu J, Patel N, Parihar J, Salmasi A, Kim W, Kim I. Concern for overtreatment using the AUA/ASTRO guideline on adjuvant radiotherapy after radical prostatectomy. BMC Urology 2014, 14: 30. PMID: 24708639, PMCID: PMC4005471, DOI: 10.1186/1471-2490-14-30.Peer-Reviewed Original ResearchConceptsAdjuvant radiotherapyRadical prostatectomyAmerican Urological AssociationSalvage radiotherapyASTRO guidelineBiochemical progression-free survivalLocal recurrence-free survivalCox proportional hazards analysisNeoadjuvant hormonal therapyPre-operative PSAUndetectable PSA levelsProgression-free survivalPositive surgical marginsProportional hazards analysisRecurrence-free survivalMultivariate Cox analysisRadiation Oncology guidelinesSeminal vesicle invasionOutcomes of observationPathologic GSPT2-3Adjuvant treatmentHormonal therapyFree survivalPSA levels